Phase 1 Study of LMY-920 BAFF CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma

What this Trial Is About

Researchers are evaluating a new treatment called LMY-920, which consists of CAR-T cells expressing the B-cell activating factor BAFF ligand, for people with relapsed or refractory multiple myeloma. This phase 1 study aims to find the recommended dose for further testing by assessing safety and treatment responses in patients whose myeloma has returned or not responded after multiple prior therapies, including other CAR-T treatments targeting BCMA. The study involves an open-label dose escalation of up to four levels of LMY-920 CAR-T cells given to participants. The maximum tolerated dose will be identified using a standard 33 design. Participants will receive their own modified T cells engineered to target the BAFF receptor family, including BCMA and other related receptors. The treatment is given as a single infusion, and participants will be closely monitored for side effects and response. During the study, participants will undergo regular assessments including blood tests, bone marrow evaluations, and disease measurements based on defined myeloma response criteria. Researchers will track safety, response rates, duration of response, progression-free and overall survival, and immune reactions over 24 months. The study includes detailed monitoring to determine the best dose and understand the treatments effects in this patient group.

LMY-920 for Treatment of Relapsed or Refractory Myeloma